Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

BACKGROUND: All the peroxisome proliferator activated receptors (PPARs) are found to be expressed in bone cells. The PPARγ agonist rosiglitazone has been shown to decrease bone mass in mice and thiazolidinediones (TZDs) have recently been found to increase bone loss and fracture risk in humans treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Syversen, Unni, Stunes, Astrid K, Gustafsson, Björn I, Obrant, Karl J, Nordsletten, Lars, Berge, Rolf, Thommesen, Liv, Reseland, Janne E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678137/
https://www.ncbi.nlm.nih.gov/pubmed/19331671
http://dx.doi.org/10.1186/1472-6823-9-10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678137/
https://www.ncbi.nlm.nih.gov/pubmed/19331671
http://dx.doi.org/10.1186/1472-6823-9-10

Ejemplares similares